Accendra Health (ACH) Proxy filing summary

Executive summary

• Completed the sale of the Products & Healthcare Services business, transforming into a focused, pure-play home-based care company as of December 31, 2025.

• Operates under two primary brands, Apria and Byram Healthcare, serving patients with acute and chronic conditions nationwide.

• Generated $10.672 billion in total revenue, $215 million in adjusted operating income, and $424 million in adjusted EBITDA for 2025.

• Reduced net debt by $46 million despite an increase in total debt by $209 million; used $102 million in operating cash flow.

• Strategic focus on technology, automation, and operational efficiency to drive growth and shareholder value.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) election of six directors for one-year terms, (2) ratification of KPMG LLP as independent auditor for 2026, (3) advisory vote on executive compensation (say-on-pay), and (4) approval of the Amended and Restated 2023 Omnibus Incentive Plan.

• Board recommends voting FOR all proposals.

• Shareholder proposals and director nominations for the 2027 meeting must comply with advance notice and eligibility requirements.

Board of directors and corporate governance

• Board reduced to six members post-divestiture for greater agility; all but the CEO are independent.

• Committees include Audit, Governance & Nominating, and Our People & Culture, all chaired by independent directors.

• Annual board and committee self-evaluations, majority voting standard for uncontested director elections, and proxy access for significant long-term shareholders.

• Stock ownership guidelines require directors to hold equity valued at four times their annual cash retainer.